Forty-seven out patients with generalized anxiety disorder by DSM-Ⅲ criteria were randomly assigned to receive ether alprazolam or placebo. The dosage of alprazolam was 1.5 to 2.0㎎ per day and treatment period was 2 weeks. Clinical evaluation with...
Forty-seven out patients with generalized anxiety disorder by DSM-Ⅲ criteria were randomly assigned to receive ether alprazolam or placebo. The dosage of alprazolam was 1.5 to 2.0㎎ per day and treatment period was 2 weeks. Clinical evaluation with Hamilton's anxiety scale and depression scale were done on the double blind basis before(baseline) and after treatment. The changes from baseline were compared between placebo and active drug groups.
The result of study showed that alprazolam produced significantly more clinical improvement than did placebo in both anxiety and depression.
The side effects as anticholinergic effects were not reported for alprazolam as well as placebo. Tolerance and withdrawal symptoms were not noted during the study period of 4 weeks.